The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Novartis
Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant unresectable or metastatic melanoma (MM).
 
Georgina V. Long
Honoraria - Bristol-Myers Squibb; Merck; Roche
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; MERCK; Novartis; Pierre Fabre; Roche/Genentech
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Roche/Genentech
 
Zeynep Eroglu
No Relationships to Disclose
 
Jeffrey R. Infante
Research Funding - Aileron Therapeutics (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Celldex (Inst); Celldex (Inst); eFFECTOR Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Janssen Oncology (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Roche (Inst); Roche (Inst); Tesaro (Inst)
 
Sapna Pradyuman Patel
Stock and Other Ownership Interests - Provectus
Honoraria - Dava Oncology; PCME, Rockpointe; PlatformQ Health
Consulting or Advisory Role - Amgen; Genentech/Roche
Speakers' Bureau - Bristol-Myers Squibb (Mexico); Merck
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Prometheus (Inst); Reata Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb (Mexico); Merck
 
Adil Daud
Stock and Other Ownership Interests - Oncosec
Honoraria - EMD Serono; Inovio Pharmaceuticals
Consulting or Advisory Role - GlaxoSmithKline; Merck; Oncosec
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck/Schering Plough (Inst); oncosec (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - patent relating to test for immunotherapy
 
Douglas Buckner Johnson
Consulting or Advisory Role - Bristol-Myers Squibb; Genoptix
Research Funding - Incyte
 
Rene Gonzalez
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Castle Biosciences; Genentech; Novartis
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Celldex (Inst); Checkmate Pharmaceuticals (Inst); Dynavax Technologies (Inst); Genentech/Roche (Inst); Incyte (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Reata Pharmaceuticals (Inst); Syndax (Inst); Takeda (Inst)
 
Richard Kefford
Honoraria - Bristol-Myers Squibb; Merck; Novartis
Consulting or Advisory Role - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Novartis (Inst); Roche (Inst); TEVA (Inst)
Speakers' Bureau - GlaxoSmithKline; Merck
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck
 
Omid Hamid
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Novartis; Roche
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Genentech; Novartis
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Genentech (Inst); Immunocore (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Rinat (Inst); Roche (Inst)
 
Lynn Mara Schuchter
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Merck (Inst)
 
Jonathan S. Cebon
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Novartis
Consulting or Advisory Role - Amgen (Inst); Bionomics; Bionomics (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Novartis; Novartis (Inst)
Research Funding - CSL Behring (Inst); GlaxoSmithKline (Inst)
Patents, Royalties, Other Intellectual Property - GlaxoSmithKline
Expert Testimony - Bristol-Myers Squibb
 
William Howard Sharfman
Consulting or Advisory Role - Merck
Research Funding - Bristol-Myers Squibb (Inst)
 
Robert R. McWilliams
Consulting or Advisory Role - Merrimack (Inst)
Research Funding - Aduro Biotech (Inst); Genentech (Inst); Lilly (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); PRISM BioLab (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Mario Sznol
Stock and Other Ownership Interests - Adaptive Biotechnologies; Amphivena; Intensity Therapeutics
Consulting or Advisory Role - Adaptimmune; Agonox; Alexion Pharmaceuticals; Amgen; Anaeropharma; Astellas Pharma; AstraZeneca/MedImmune; Biodesix; Bristol-Myers Squibb; Genentech/Roche; Immune Design; Immune Design; Inovio Pharmaceuticals; Janssen Oncology; Kyowa Hakko Kirin; Lilly; Lion Biotechnologies; Lycera; Merck Sharp & Dohme; Merus; Modulate Pharma; Nektar; Novartis; Omniox; pfizer; Prometheus; Seagen; Symphony Evolution; Theravance; Vaccinex
Other Relationship - AcademicCME; Clinical Care Options; Dava Oncology; Haymarket Media; Imedex; Physicans' Education Resource; Prime Oncology; Research to Practice; TRM Oncology; Vindico
 
Jeffrey S. Weber
Stock and Other Ownership Interests - Altor BioScience; Celldex; CytomX Therapeutics
Honoraria - Abbvie; Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Ichor Medical Systems; Lion Biotechnologies; Medivation; Merck; Merck; Nektar; Novartis; Pieris Pharmaceuticals; Roche
Consulting or Advisory Role - Abbvie; Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Ichor Medical Systems; Lion Biotechnologies; Medivation; Merck; Merck; Nektar; Novartis; Pieris Pharmaceuticals; Roche
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - named on a patent from Biodesix for a PD-1 antibody biomarker; Named on a patent submitted by Moffitt Cancer Center for an IPILIMUMAB biomarker
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Daiichi Sankyo; Genentech; GlaxoSmithKline; Lion Biotechnologies; Merck; Merck; Novartis; Pieris Pharmaceuticals; Roche
 
Bijoyesh Mookerjee
Employment - GlaxoSmithKline; Novartis
Stock and Other Ownership Interests - AstraZeneca; GlaxoSmithKline; Incyte; Novartis
 
Eduard Gasal
Employment - Novartis
Stock and Other Ownership Interests - Amgen; Novartis
 
Suman Redhu
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Keith T. Flaherty
No Relationships to Disclose